I-Paxlovid iwumuthi wophenyo osetshenziselwa ukwelapha i-COVID-19 emaphakathi kuya kokumaphakathi kubantu abadala nasezinganeni [ezineminyaka engu-12 ubudala nangaphezulu ezinesisindo esingamakhilogremu angama-88 (40 kg)] ngemiphumela emihle yokuhlolwa kwegciwane okuqondile kwe-SARS-CoV-2, futhi abasengozini enkulu yokudlulela ku-COVID-19 enzima, okuhlanganisa ukulaliswa esibhedlela noma ukufa. I-Paxlovid iyaphenywa ngoba isacwaningwa. Kunolwazi olulinganiselwe mayelana nokuphepha nokusebenza kahle kokusebenzisa i-Paxlovid ukwelapha abantu abane-COVID-19 emaphakathi kuya kokumaphakathi.
I-FDA igunyaze ukusetshenziswa okuphuthumayo kwe-Paxlovid ekwelapheni i-COVID-19 emaphakathi kuya kokumaphakathi kubantu abadala nasezinganeni [ezineminyaka engu-12 ubudala nangaphezulu ezinesisindo esingamakhilogremu angama-88 (40 kg)] ngokuhlolwa ukuthi unalo yini leli gciwane. kubangela i-COVID-19, futhi abasengozini enkulu yokudlulela ku-COVID-19 enzima, okuhlanganisa ukulaliswa esibhedlela noma ukufa, ngaphansi kwe-EUA.

I-Paxlovid akuwona umuthi ogunyazwe yi-FDA e-United States. Khuluma nomhlinzeki wakho wokunakekelwa kwezempilo mayelana nezinketho zakho noma uma unemibuzo. Kuyisinqumo sakho ukuthatha i-Paxlovid.

I-Paxlovid iqukethe imithi emibili: i-nirmatrelvir ne-ritonavir.

I-Nirmatrelvir [PF-07321332] iyi-SARS-CoV-2 main protease (Mpro) inhibitor (eyaziwa nangokuthi i-SARS-CoV2 3CL protease inhibitor) esebenza ngokuvimbela ukuphindaphindeka kwegciwane ezigabeni zokuqala zesifo ukuvimbela ukuqhubekela phambili ku-COVID- 19.

I-Ritonavir isetshenziswa ngokubambisana ne-nirmatrelvir ukusiza ukubambezela i-metabolism yayo ukuze ihlale isebenza emzimbeni isikhathi eside ekugxilweni okuphezulu ukusiza ukulwa naleli gciwane.